PK Study of T-817 in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the single-dose pharmacokinetics (PK) of T-817 and
T-817M5 (metabolite of T-817) in subjects with mild, moderate or severe hepatic impairment
compared to matched healthy control subjects.
The secondary objective is to determine the safety and tolerability of single-dose T -817MA
(Maleate salt of T-817) in subjects with mild, moderate or severe hepatic impairment.
Phase:
Phase 1
Details
Lead Sponsor:
FUJIFILM Toyama Chemical Co., Ltd. Toyama Chemical Co., Ltd.